Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Dec 02, 2019 9:02am

172 Views

Post# 30412511

RE:Conference and Webcast details

Holy smokes! Those are some pretty strong statements. I can't wait for Thursday CTAD results!

First sub-title of news release is:

"Apabetalone treatment improves cognition in CVD patients with diabetes"

Then, they quote Dr. Cummings:

"The effects seen in the BETonMACE trial for those with cognitive impairment are very promising and suggest that epigenetic modulators such as apabetalone may represent an important and novel approach to treatment of cognitive disorders"

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale